Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma


ABSTRACT: To date, there are no known prognostic markers identified in patients with fusion gene-negative rhabdomyosarcoma. This study validates the 5-gene (MG5) signature as a prognostic marker in patients with fusion negative intermediate-risk rhabdomyosarcoma clearly stratifying this otherwise clinically homogenous population of patients into two risk groups based on outcome. In addition, this analysis was performed using nCounter assay on paraffin embedded tissues and the results were concordant to previously published results using frozen tissues in a different patient cohort. Therefore, this work holds tremendous translational relevance as the MG5 signature can be reliably assessed in readily available paraffin embedded tissues of fusion gene-negative rhabdomyosarcoma patients in prospective clinical trials to stratify them into prognostic risk groups as well as to potentially tailor future therapy based on these risk groups.

ORGANISM(S): Homo sapiens

SUBMITTER: edoardo missiaglia 

PROVIDER: E-MTAB-3580 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Hingorani Pooja P   Missiaglia Edoardo E   Shipley Janet J   Anderson James R JR   Triche Timothy J TJ   Delorenzi Mauro M   Gastier-Foster Julie J   Wing Michele M   Hawkins Douglas S DS   Skapek Stephen X SX  

Clinical cancer research : an official journal of the American Association for Cancer Research 20151001 20


<h4>Purpose</h4>Pediatric rhabdomyosarcoma (RMS) has two common histologic subtypes: embryonal (ERMS) and alveolar (ARMS). PAX-FOXO1 fusion gene status is a more reliable prognostic marker than alveolar histology, whereas fusion gene-negative (FN) ARMS patients are clinically similar to ERMS patients. A five-gene expression signature (MG5) previously identified two diverse risk groups within the fusion gene-negative RMS (FN-RMS) patients, but this has not been independently validated. The goal o  ...[more]

Similar Datasets

2014-08-22 | E-GEOD-54099 | biostudies-arrayexpress
2014-08-22 | E-GEOD-54100 | biostudies-arrayexpress
2015-04-28 | E-GEOD-68306 | biostudies-arrayexpress
2016-07-06 | E-GEOD-84010 | biostudies-arrayexpress
2016-04-02 | E-GEOD-79850 | biostudies-arrayexpress
2011-11-22 | E-MTAB-863 | biostudies-arrayexpress
2011-11-22 | E-MTAB-864 | biostudies-arrayexpress
2013-04-19 | E-GEOD-41970 | biostudies-arrayexpress
2016-06-01 | E-GEOD-66533 | biostudies-arrayexpress
2011-11-26 | E-GEOD-25727 | biostudies-arrayexpress